199 related articles for article (PubMed ID: 28905323)
21. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients.
Govindaraj C; Tan P; Walker P; Wei A; Spencer A; Plebanski M
Clin Cancer Res; 2014 Feb; 20(3):724-35. PubMed ID: 24297862
[TBL] [Abstract][Full Text] [Related]
22. A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.
Assouline S; Michaelis LC; Othus M; Hay AE; Walter RB; Jacoby MA; Schroeder MA; Uy GL; Law LY; Cheema F; Sweet KL; Asch AS; Liu JJ; Moseley AB; Maher T; Kingsbury LL; Fang M; Radich J; Little RF; Erba HP
Leuk Lymphoma; 2023 Feb; 64(2):473-477. PubMed ID: 36517990
[No Abstract] [Full Text] [Related]
23. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
24. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Bazinet A; Darbaniyan F; Jabbour E; Montalban-Bravo G; Ohanian M; Chien K; Kadia T; Takahashi K; Masarova L; Short N; Alvarado Y; Yilmaz M; Ravandi F; Andreeff M; Kanagal-Shamanna R; Ganan-Gomez I; Colla S; Qiao W; Huang X; McCue D; Mirabella B; Kantarjian H; Garcia-Manero G
Lancet Haematol; 2022 Oct; 9(10):e756-e765. PubMed ID: 36063832
[TBL] [Abstract][Full Text] [Related]
25. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
[TBL] [Abstract][Full Text] [Related]
26. Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study.
Xu Y; Guo R; Miao M; Zhang G; Lan J; Jin J
Invest New Drugs; 2022 Oct; 40(5):1117-1124. PubMed ID: 35834039
[TBL] [Abstract][Full Text] [Related]
27. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept.
Scott BL; Ramakrishnan A; Storer B; Becker PS; Petersdorf S; Estey EH; Deeg HJ
Br J Haematol; 2010 Mar; 148(6):944-7. PubMed ID: 20064151
[TBL] [Abstract][Full Text] [Related]
28. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone.
Almeida AM; Pierdomenico F
Leuk Res; 2012 Sep; 36(9):e211-3. PubMed ID: 22622173
[No Abstract] [Full Text] [Related]
29. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
Usuki K; Ohtake S; Honda S; Matsuda M; Wakita A; Nawa Y; Takase K; Maeda A; Sezaki N; Yokoyama H; Takada S; Hirano D; Tomikawa T; Sumi M; Yano S; Handa H; Ota S; Fujita H; Fujimaki K; Mugitani A; Kojima K; Kajiguchi T; Fujimoto K; Asou N; Usui N; Ishikawa Y; Katsumi A; Matsumura I; Miyazaki Y; Kiyoi H
Int J Hematol; 2024 Feb; 119(2):130-145. PubMed ID: 38091231
[TBL] [Abstract][Full Text] [Related]
30. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.
Adès L; Itzykson R; Fenaux P
Semin Hematol; 2012 Oct; 49(4):323-9. PubMed ID: 23079062
[TBL] [Abstract][Full Text] [Related]
31. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Prebet T; Sun Z; Ketterling RP; Zeidan A; Greenberg P; Herman J; Juckett M; Smith MR; Malick L; Paietta E; Czader M; Figueroa M; Gabrilove J; Erba HP; Tallman MS; Litzow M; Gore SD;
Br J Haematol; 2016 Feb; 172(3):384-91. PubMed ID: 26577691
[TBL] [Abstract][Full Text] [Related]
32. A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
Sekeres MA; Schuster M; Joris M; Krauter J; Maertens J; Breems D; Gyan E; Kovacsovics T; Verma A; Vyas P; Wang ES; Ching K; O'Brien T; Gallo Stampino C; Ma WW; Kudla A; Chan G; Zeidan AM
Ann Hematol; 2022 Aug; 101(8):1689-1701. PubMed ID: 35488900
[TBL] [Abstract][Full Text] [Related]
33. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome.
Tan P; Wei A; Mithraprabhu S; Cummings N; Liu HB; Perugini M; Reed K; Avery S; Patil S; Walker P; Mollee P; Grigg A; D'Andrea R; Dear A; Spencer A
Blood Cancer J; 2014 Jan; 4(1):e170. PubMed ID: 24413064
[TBL] [Abstract][Full Text] [Related]
34. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Griffiths EA; Gore SD
Semin Hematol; 2008 Jan; 45(1):23-30. PubMed ID: 18179966
[TBL] [Abstract][Full Text] [Related]
35. Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.
Tibes R; Kosiorek HE; Dueck AC; Palmer J; Sproat L; Bogenberger J; Hashmi S; Mesa R; Hogan W; Litzow MR; Al-Kali A
Cancer; 2023 Aug; 129(15):2321-2330. PubMed ID: 37042080
[TBL] [Abstract][Full Text] [Related]
36. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.
Ghobrial IM; Campigotto F; Murphy TJ; Boswell EN; Banwait R; Azab F; Chuma S; Kunsman J; Donovan A; Masood F; Warren D; Rodig S; Anderson KC; Richardson PG; Weller E; Matous J
Blood; 2013 Feb; 121(8):1296-303. PubMed ID: 23287861
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome.
Dimicoli S; Jabbour E; Borthakur G; Kadia T; Estrov Z; Yang H; Kelly M; Pierce S; Kantarjian H; Garcia-Manero G
Am J Hematol; 2012 Jan; 87(1):127-9. PubMed ID: 22072492
[TBL] [Abstract][Full Text] [Related]
38. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
Navada SC; Garcia-Manero G; OdchimarReissig R; Pemmaraju N; Alvarado Y; Ohanian MN; John RB; Demakos EP; Zbyszewski PS; Maniar M; Woodman RC; Fruchtman SM; Silverman LR
Leuk Res; 2020 Jul; 94():106369. PubMed ID: 32442785
[TBL] [Abstract][Full Text] [Related]
39. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Kantarjian H; Oki Y; Garcia-Manero G; Huang X; O'Brien S; Cortes J; Faderl S; Bueso-Ramos C; Ravandi F; Estrov Z; Ferrajoli A; Wierda W; Shan J; Davis J; Giles F; Saba HI; Issa JP
Blood; 2007 Jan; 109(1):52-7. PubMed ID: 16882708
[TBL] [Abstract][Full Text] [Related]
40. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
Wehmeyer J; Zaiss M; Losem C; Schmitz S; Niemeier B; Harde J; Hannig CV; Harich HD; Müller J; Klausmann M; Tessen HW; Potthoff K
Eur J Haematol; 2018 Dec; 101(6):766-773. PubMed ID: 30091166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
